An interventional study of Needle guiding robot in Carcinoma, Hepatocellular, sponsored by Asan Medical Center. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-09-10.
Sponsored by Asan Medical Center · Not applicable, Interventional, and Treatment
The needle guiding robot helps targeting of radiofrequency ablation needles by matching computed tomography images and patients' bodies. Actual insertion of needles will be performed by doctors. This study evaluates the safety and efficacy of needle targeting on patients with hepatocellular carcinoma.
A robotic system has been developed that includes a needle-path planning system and a needle-guiding robot arm with computed tomography (CT) guidance. The robot consists of robot base, 5-axis robot arm with guiding end-effector and path-planner. Optical tracking system with a custom-designed registration jig is used for the spatial registration and validation. Advantages of the robotic system would be accurate targeting with diverse angulation of the robot arm in CT-guided tumor ablation. Furthermore, robotic intervention might potentially decrease procedure time and radiation exposure to patients. The purpose of this clinical trial with patients with hepatocelluar carcinoma is to assess the safety and efficacy of our CT-guided needle-guiding robot.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's planned enrollment of 20 is below the median of 45 across 5,170 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →Asan Medical Center is the lead sponsor of 562 studies on the registry; 71 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
CT-guided radiofrequency ablation of hepatocellular carcinoma using needle guiding robot
Device: Needle guiding robot
This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.
Total radiation exposure (DLP, mGy*cm)
Sum of radiation exposures measured during the radiofrequency ablation
Time frame: At time of radiofrequency ablation
Number of repositioning of radiofrequency electrode
Number of repositioning of radiofrequency electrode in order to correct targeting discrepancy untile properly placed in to the target tumor
Time frame: At time of radiofrequency ablation
Targeting error
Distance between the target and the electrode tip
Time frame: At time of the 1st insertion of the electrode
Procedure time
Total period of time from the installation of needle guiding robot to patient's transfer after the procedure
Time frame: At time of radiofrequency ablation
Plan to share: No
This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Asan Medical Center